1. Immunology/Inflammation
  2. NOD-like Receptor (NLR)
  3. MCC950

MCC950  (Synonyms: CP-456773; CRID3)

Cat. No.: HY-12815 Purity: ≥98.0%
COA Handling Instructions

MCC950 (CP-456773; CRID3) is a potent and selective NLRP3 inhibitor with IC50s of 7.5 and 8.1 nM in BMDMs and HMDMs, respectively.

For research use only. We do not sell to patients.

MCC950 Chemical Structure

MCC950 Chemical Structure

CAS No. : 210826-40-7

Size Stock
100 mg   Get quote  
250 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Other In-stock Forms of MCC950:

Other Forms of MCC950:

Top Publications Citing Use of Products

152 Publications Citing Use of MCE MCC950


    MCC950 purchased from MCE. Usage Cited in: J Am Heart Assoc. 2017 Sep 4;6(9). pii: e006347.  [Abstract]

    Cells are pretreated with YVAD(10 μM) or MCC950 (10 μM) for 2 hours, and then exposed to TMAO (600 μM) for a further 24 hours. Expression of IL-1β, ICAM-1, MMP-9, and caspase-1 p20 is detected via Western blot.

    MCC950 purchased from MCE. Usage Cited in: Dig Dis Sci. 2018 Jan;63(1):81-91.  [Abstract]

    The expression of various molecules in pyroptotic and apoptotic pathways is detected by western blot. Representative bands from densitometric analysis in experimental groups are presented. M, MCC950 group (an inhibitor of NLRP3).

    MCC950 purchased from MCE. Usage Cited in: Biofactors. 2018 Mar;44(2):123-136.  [Abstract]

    NLRP3, Casp1 p20, IL-1b, and ICAM-1 protein levels are assessed in the cell lysates by Western blotting.

    MCC950 purchased from MCE. Usage Cited in: J Neuroinflammation. 2018 Mar 24;15(1):95.  [Abstract]

    Chronic PVN infusion of MCC950 significantly decreases apoptosis-associated speck-like protein (ASC), pro-caspase-1, and IL-1β expression in high-salt diet rats.

    MCC950 purchased from MCE. Usage Cited in: Neurobiol Dis. 2018 Sep;117:15-27.  [Abstract]

    Effect of MCC950 on the expression of NLRP3 inflammasome components and substrates after traumatic brain injury (TBI).

    MCC950 purchased from MCE. Usage Cited in: Clin Exp Immunol. 2018 Nov;194(2):231-243.  [Abstract]

    MCC950 treatment inhibits Nucleotide-binding, oligomerization domain (NOD)-like receptor family, pyrin domain containing 3 (NLRP3) inflammasome pathway activation.

    MCC950 purchased from MCE. Usage Cited in: Biochim Biophys Acta. 2017 Oct 3;1864(1):1-10.  [Abstract]

    MCC950 or vehicle control (PBS) is administered at 1, 4 and 6 day after Ang II infusion in the absence or presence of EMD638683. Representative images and quantification of picrosirius red-stained collagen in the heart at 7 days after Ang II infusion.

    MCC950 purchased from MCE. Usage Cited in: Molecules. 2018 Feb 27;23(3). pii: E522.  [Abstract]

    Effects of MCC950 on hippocampal NLRP3 inflammasome activation in db/db mice. Western blot analysis of NLRP3 inflammasome-associated NLRP3, ASC, IL-1β, and β-actin are performed in the hippocampus of each group.

    MCC950 purchased from MCE. Usage Cited in: Cell Death Dis. 2018 Sep 20;9(10):946.   [Abstract]

    The efficiency of MCC950, and its effect on caspase-1 activation and IL-1β production in As2O3-treated HepG2 cells.

    MCC950 purchased from MCE. Usage Cited in: EMBO J. 2022 Oct 17;e111173.  [Abstract]

    BMDMs isolated from Phb1F/F mice and Phb1MyeKO mice are incubated with MCC950 (50 nM) for 30 min and are subsequently stimulated by LPS (200 ng/ml) for 6 h and ATP (4 mM) for 45 min. Protein levels in whole cell lysates and culture medium are detected by WB assay.
    • Biological Activity

    • Protocol

    • Purity & Documentation

    • References

    • Customer Review


    MCC950 (CP-456773; CRID3) is a potent and selective NLRP3 inhibitor with IC50s of 7.5 and 8.1 nM in BMDMs and HMDMs, respectively.

    IC50 & Target

    IC50: 7.5 nM (NLRP3, in BMDMs), 8.1 nM (NLRP3, in HMDMs)[1]

    In Vitro

    MCC950 blocks canonical and non-canonical NLRP3 activation at nanomolar concentrations. MCC950 specifically inhibits NLRP3 but not AIM2, NLRC4 or NLRP1 activation. The effect of MCC950 on NLRP3 inflammasome activation is tested in mouse bone marrow derived macrophages (BMDM) and human monocyte derived macrophages (HMDM). The IC50 of MCC950 in BMDM is approximately 7.5 nM, while in HMDM it has a similar inhibitory capacity (IC50=8.1 nM). MCC950 also dose dependently inhibit IL-1β but not TNF-α secretion.MCC950 specifically blocks caspase-11-directed NLRP3 activation and IL-1β secretion upon stimulation of the non-canonical pathway. NLRC4-stimulated IL-1β and TNF-α secretion (as activated by Salmonella typhimurium) are not inhibited by MCC950 even at a concentration of 10 µM. MCC950 does not inhibit caspase-1 activation or IL-1β processing in response to S. typhimurium. The expression of pro-caspase-1 and pro-IL-1β in cell lysates is not substantially affected by MCC950 treatment[1].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    In Vivo

    MCC950 reduces Interleukin-1p (IL-1β) production and attenuates the severity of experimental autoimmune encephalomyelitis (EAE), a disease model of multiple sclerosis. Pre-treatment with MCC950 reduces serum concentrations of IL-1β and IL-6 while it does not considerably decrease the amount of TNF-α. Treatment of mice with MCC950 delays the onset and reduced the severity of EAE. Intracellular cytokine staining and FACS analysis of brain mononuclear cells from mice sacrificed on day 22 shows modestly reduced frequencies of IL-17 and IFN-γ producing CD3+ T cells in MCC950 treated mice in comparison with PBS-treated mice. IFN-γ and particularly IL-17 producing cell numbers are also reduced in both the CD4+ and γδ+ sub-populations of CD3+ T cells[1].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Molecular Weight




    CAS No.



    Room temperature in continental US; may vary elsewhere.

    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 6 months
    -20°C 1 month
    Solvent & Solubility
    In Vitro: 

    H2O : 50 mg/mL (123.62 mM; Need ultrasonic)

    DMSO : ≥ 28 mg/mL (69.22 mM)

    *"≥" means soluble, but saturation unknown.

    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 2.4723 mL 12.3616 mL 24.7231 mL
    5 mM 0.4945 mL 2.4723 mL 4.9446 mL
    10 mM 0.2472 mL 1.2362 mL 2.4723 mL
    *Please refer to the solubility information to select the appropriate solvent.
    In Vivo:
    • 1.

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% saline

      Solubility: ≥ 2.5 mg/mL (6.18 mM); Clear solution

    • 2.

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in saline)

      Solubility: ≥ 2.5 mg/mL (6.18 mM); Clear solution

    • 3.

      Add each solvent one by one:  10% DMSO    90% corn oil

      Solubility: ≥ 2.5 mg/mL (6.18 mM); Clear solution

    *All of the co-solvents are available by MCE.
    Purity & Documentation

    Purity: 99.43%

    Cell Assay

    BMDM are seeded at 5×105/mL or 1×106/mL, HMDM at 5×105/mL and PBMC at 2×106/mL or 5×106/mL in 96 well plates. The following day the overnight medium is replaced and cells are stimulated with 10 ng/mL LPS from Escherichia coli serotype EH100 (ra) TLRgrad for 3 h. Medium is removed and replaced with serum free medium (SFM) containing DMSO (1:1,000), MCC950 (0.001-10 µM), Parthenolide (10 µM) or Bayer cysteinyl leukotriene receptor antagonist 1-(5-carboxy-2{3-[4-(3-cyclohexylpropoxy)phenyl]propoxy}benzoyl)piperidine-4-carboxylic acid (40 µM) for 30 min. Cells are then stimulated with inflammasome activators: 5 mM adenosine 5’-triphosphate disodium salt hydrate (ATP) (1 h), 1 µg/mL Poly(deoxyadenylic-thymidylic) acid sodium salt (Poly dA:dT) transfected with Lipofectamine 200 (3-4 h), 200 µg/mL MSU (overnight) and 10 µM nigericin (1 h) or S. typhimurium UK-1 strain. Cells are also stimulated with 25 µg/mL Polyadenylic-polyuridylic acid (4 h). For non-canonical inflammasome activation cells are primed with 100 ng/mL Pam3CSK4 for 4 h, medium is removed and replaced with SFM containing DMSO or MCC950 and 2 µg/mL LPS is transfected using 0.25% FuGENE for 16 h. Supernatants are removed and analysed using ELISA kits. LDH release is measured using the CytoTox96 non-radioactive cytotoxicity assay[1].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Administration

    C57BL/6 mice are immunized subcutaneously with 150 µg of MOG peptide 35-55 emulsified in CFA containing 4 mg/mL (0.4.mg/mouse) of heat-killed MTB. Mice are injected i.p. with 500 ng pertussis toxin (PT: kaketsuken) on days 0 and 2. MCC950 is administered i.p. to mice (10 mg/kg) at induction of the disease, day 0, 1 and 2 and every 2 days thereafter. Control mice are administered vehicle (PBS) at the same time points. Mice are observed for clinical signs of disease daily (unblinded). Disease severity is scored as follows: no clinical signs, 0; limp tail, 1; ataxic gait, 2; hind limb weakness, 3; hind limb paralysis, 4; and tetra paralysis, 5.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name



    Applicant Name *


    Email address *

    Phone number *


    Organization name *

    Department *


    Requested quantity *

    Country or Region *



    Bulk Inquiry

    Inquiry Information

    Product Name:
    Cat. No.:
    MCE Japan Authorized Agent: